• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Acorda Therapeutics - Articles and news items

tozadenant

Acorda to acquire Biotie; gains rights to tozadenant

Industry news / 19 January 2016 / Victoria White

In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +